Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

7.7%

3 terminated/withdrawn out of 39 trials

Success Rate

81.3%

-5.3% vs industry average

Late-Stage Pipeline

18%

7 trials in Phase 3/4

Results Transparency

8%

1 of 13 completed trials have results

Key Signals

6 recruiting1 with results

Enrollment Performance

Analytics

N/A
11(37.9%)
Phase 2
9(31.0%)
Phase 3
6(20.7%)
Phase 1
1(3.4%)
Phase 4
1(3.4%)
Early Phase 1
1(3.4%)
29Total
N/A(11)
Phase 2(9)
Phase 3(6)
Phase 1(1)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (39)

Showing 20 of 39 trials
NCT06560697Not ApplicableRecruiting

Cervical Boost by Ablative Stereotactic Radiotherapy (SABR) vs Brachytherapy in Patients With Cervical Carcinoma

Role: lead

NCT07025213Not ApplicableRecruiting

Metabolic Effect of Exercise and Diet in Endometrial Cancer Patients Eligible for Staging Surgery.

Role: lead

NCT02446652Phase 3Withdrawn

Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer

Role: lead

NCT04165460Not ApplicableEnrolling By Invitation

Effect of Two Cognitive-Behavioral Interventions on Cervical Cancer Patients

Role: lead

NCT03101995Phase 2Recruiting

Assessment of Gemcitabine as Chemoradiotherapy in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease

Role: lead

NCT06156514Phase 3Recruiting

Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer

Role: lead

NCT03994055Not ApplicableCompleted

Effect of an Anti-inflammatory Diet on Patients With Cervical Cancer

Role: lead

NCT06080841Not ApplicableRecruiting

Curcumin Supplementation in Cervical Cancer

Role: lead

NCT06206083Recruiting

Molecular Classification in Mexican Patients With Endometrial Cancer and Its Impact on Prognosis

Role: lead

NCT04070976Not ApplicableUnknown

Chemotherapy and Pelvic Hypofractionated Radiation Followed by Brachytherapy for Cervical Cancer

Role: lead

NCT03899376Not ApplicableUnknown

A Trial Comparing Acute Toxicity in Patients With Gynecological Cancer Treated With VMAT

Role: lead

NCT04067882Unknown

Validation of the Genetic Signature 354849 as a Prognostic Method

Role: lead

NCT03750539Not ApplicableUnknown

Chemotherapy and Pelvic Hypofractionated Radiation Followed by Surgery Cervical Cancer

Role: lead

NCT05736315Not ApplicableCompleted

Use of a Fermented Dairy Beverage in Cervical Cancer Patients Undergoing Concurrent Chemoradiation Therapy

Role: lead

NCT03296553Phase 2Completed

Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.

Role: lead

NCT03100409Not ApplicableTerminated

Effect of a Low Residue Diet in Comparison to the Dietetic Recommendations From the INCan in Cervical Cancer Patients

Role: lead

NCT04537273Completed

Clinical and Pathological Characteristics as Prognostic Factors in Locally Advanced Cervical Cancer

Role: lead

NCT03788850Completed

Factors Associated With Residual Disease In The Central Cone

Role: lead

NCT04087785Completed

microRNA Profile in Early-stage Cervical Cancer

Role: lead

NCT03229824Not ApplicableCompleted

Use of Clorhexidine Dressings to Reduce Surgical Site Infections in Breast Cancer Surgery. A Controlled Clinical Trial

Role: lead